AU776864B2 - Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence - Google Patents

Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence Download PDF

Info

Publication number
AU776864B2
AU776864B2 AU32221/00A AU3222100A AU776864B2 AU 776864 B2 AU776864 B2 AU 776864B2 AU 32221/00 A AU32221/00 A AU 32221/00A AU 3222100 A AU3222100 A AU 3222100A AU 776864 B2 AU776864 B2 AU 776864B2
Authority
AU
Australia
Prior art keywords
dam
mutation
bacteria
immunogenic composition
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32221/00A
Other languages
English (en)
Other versions
AU3222100A (en
Inventor
Douglas M. Heithoff
David A. Low
Michael J. Mahan
Robert L. Sinsheimer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU3222100A publication Critical patent/AU3222100A/en
Application granted granted Critical
Publication of AU776864B2 publication Critical patent/AU776864B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU32221/00A 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence Ceased AU776864B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24195199A 1999-02-02 1999-02-02
US09/241951 1999-02-02
US30560399A 1999-05-05 1999-05-05
US09/305603 1999-05-05
US49561400A 2000-02-01 2000-02-01
US09/495614 2000-02-01
PCT/US2000/002866 WO2000045840A1 (fr) 1999-02-02 2000-02-02 Compositions et methodes de traitement et de prevention d'infections bacteriennes pathogenes basees sur le role essentiel de la methylation de l'adn dans la virulence bacterienne

Publications (2)

Publication Number Publication Date
AU3222100A AU3222100A (en) 2000-08-25
AU776864B2 true AU776864B2 (en) 2004-09-23

Family

ID=27399537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32221/00A Ceased AU776864B2 (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence

Country Status (8)

Country Link
EP (1) EP1150711A1 (fr)
JP (1) JP2002536339A (fr)
AU (1) AU776864B2 (fr)
BR (1) BR0007966A (fr)
CA (1) CA2359469A1 (fr)
MX (1) MXPA01007747A (fr)
NZ (1) NZ512685A (fr)
WO (1) WO2000045840A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6602680B2 (en) 2000-07-14 2003-08-05 The Regents Of The University Of California Production of gabaergic cells
GB0029379D0 (en) * 2000-12-01 2001-01-17 Arrow Therapeutics Ltd A method for identifying enzyme inhibitors
ITRM20010295A1 (it) * 2001-05-30 2002-12-02 Stresstech S R L Metodo per ottenere microrganismi patogeni non virulenti attraverso una modificazione dello stato fisico e/o dinamico delle loro membrane bi
JP2003189861A (ja) * 2001-12-25 2003-07-08 Japan Science & Technology Corp 細菌の運動性関連遺伝子群発現の制御
WO2021030268A2 (fr) 2019-08-09 2021-02-18 Nutcracker Therapeutics, Inc. Appareil microfluidique et ses procédés d'utilisation
WO2021107013A1 (fr) * 2019-11-29 2021-06-03 国立研究開発法人理化学研究所 Composition d'adjuvant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAWER, R. ET AL. ARCHIVES OF MICRO. (1998) VOL.169 PP530-33 *
TORREBLANCA, J. ET AL. GENETICS VOL.144 PP 15-16 (SEPT.1996) *

Also Published As

Publication number Publication date
WO2000045840A1 (fr) 2000-08-10
BR0007966A (pt) 2001-11-06
JP2002536339A (ja) 2002-10-29
CA2359469A1 (fr) 2000-08-10
AU3222100A (en) 2000-08-25
EP1150711A1 (fr) 2001-11-07
MXPA01007747A (es) 2002-07-02
WO2000045840A8 (fr) 2001-03-22
NZ512685A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
US6399074B1 (en) Live attenuated salmonella vaccines to control avian pathogens
Wyszyńska et al. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter
JP2640525B2 (ja) 無毒の微生物とその使用
JPS62501211A (ja) 新規な非復帰性サルモネラ生ワクチン
US20110052635A1 (en) Live attenuated salmonella vaccine
CN104797268B (zh) 一种新型志贺氏菌减毒活疫苗
US9399057B2 (en) Salmonella vaccine
US6902906B1 (en) Bacteria attenuated by a non-reverting mutation in each of the aroC, ompF and ompC genes, useful as vaccines
AU783508B2 (en) Salmonella vaccine
US7026155B2 (en) Method of reducing bacterial proliferation
US20020068068A1 (en) Method of creating antibodies and compositions used for same
US20020076417A1 (en) Attenuated bacteria with altered DNA adenine methylase activity
AU776864B2 (en) Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence
US20020081317A1 (en) Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope
US20020086032A1 (en) Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
US20020077272A1 (en) Reducing bacterial virulence
JP2005519872A (ja) サルモネラ・ワクチン
JP2009529895A (ja) 弱毒化サルモネラ生ワクチン
US20220218810A1 (en) New immunogenic compositions
ZA200105305B (en) Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence.
KR20010039651A (ko) 백신용 약독화 생박테리아
Choi et al. Salmonella enterica serovar Typhimurium ruvB mutant can confer protection against salmonellosis in mice
KR20080105099A (ko) 약독화 살모넬라 생백신
Yan et al. A Vibrio cholerae serogroup O1 vaccine candidate against CTXETΦ infection
Guzman et al. Vaccines against Infections Caused by Salmonella, Shigella, and Pathogenic Escherichia coli